The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
What are the key updates to the GRAPPA guidelines, and how should HCPs be using them?
Featured:
Laura Coates
Kathleen GallantThe Psoriasis and Psoriatic Arthritis Hub was pleased to speak with Kathleen Gallant, International Federation of Psoriasis Associations (IFPA), Pittsburg, US, and Laura Coates, University of Oxford, Oxford, UK. We asked, What are the key updates to the GRAPPA guidelines, and what is your advice on how HCPs should use them?
What are the key updates to the GRAPPA guidelines, and how should HCPs be using them?
Coates begins by addressing the key updates of the Group of Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) guidelines, focusing on new data gathered around existing therapies, as well as new therapies, such as new mode of action biological drugs/targeted synthetic drugs. Gallant and Coates go on to discuss how the guidance might impact existing treatment regimens and how this differs to previous treatment recommendations. Coates highlights the potential benefits the guideline updates may have, allowing for a more targeted approach when it comes to selecting drugs for individuals and being able to better factor in comorbidities and associated conditions during treatment selection. Coates also touches on the fact that the updates are international recommendations and flexible, enabling them to be applied to the various approvals and healthcare settings in different countries. Finally, Gallant and Coates discuss how patients could talk about treatment options with their HCPs, and touch upon the importance of conversations and shared decision-making around therapeutic choice.